Cargando…
Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
BACKGROUND: Approximately 15% of patients with diffuse large B‐cell lymphoma (DLBCL) experience refractory or early relapsed disease after initial rituximab‐containing chemoimmunotherapy is regarded as a primary refractory disease. Although the standard treatment for relapsed DLBCL is high‐dose chem...
Autores principales: | Suzuki, Tomotaka, Maruyama, Dai, Miyagi‐Maeshima, Akiko, Nomoto, Junko, Tajima, Kinuko, Ito, Yuta, Hatta, Shunsuke, Yuda, Sayako, Makita, Shinichi, Fukuhara, Suguru, Munakata, Wataru, Suzuki, Tatsuya, Taniguchi, Hirokazu, Izutsu, Koji, Kobayashi, Yukio, Tobinai, Kensei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335825/ https://www.ncbi.nlm.nih.gov/pubmed/34105893 http://dx.doi.org/10.1002/cam4.4062 |
Ejemplares similares
-
Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors
por: Suzuki, Tomotaka, et al.
Publicado: (2020) -
The role of local radiotherapy following rituximab‐containing chemotherapy in patients with transformed indolent B‐cell lymphoma
por: Nozaki, Kenji, et al.
Publicado: (2020) -
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab
por: Ito, Yuta, et al.
Publicado: (2018) -
Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
por: Yuda, Sayako, et al.
Publicado: (2016) -
Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma
por: Shichijo, Takafumi, et al.
Publicado: (2020)